BioDelivery Sciences Shares Outstanding 2006-2021 | BDSI

BioDelivery Sciences shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
BioDelivery Sciences Annual Shares Outstanding
(Millions of Shares)
2020 105
2019 83
2018 63
2017 56
2016 54
2015 52
2014 48
2013 38
2012 31
2011 28
2010 23
2009 21
2008 19
2007 18
2006 13
2005 8
BioDelivery Sciences Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 103
2021-03-31 105
2020-12-31 105
2020-09-30 106
2020-06-30 108
2020-03-31 107
2019-12-31 83
2019-09-30 105
2019-06-30 84
2019-03-31 71
2018-12-31 63
2018-09-30 65
2018-06-30 59
2018-03-31 58
2017-12-31 56
2017-09-30 56
2017-06-30 55
2017-03-31 55
2016-12-31 54
2016-09-30 54
2016-06-30 54
2016-03-31 52
2015-12-31 52
2015-09-30 53
2015-06-30 52
2015-03-31 52
2014-12-31 48
2014-09-30 50
2014-06-30 49
2014-03-31 44
2013-12-31 38
2013-09-30 38
2013-06-30 38
2013-03-31 38
2012-12-31 31
2012-09-30 30
2012-06-30 31
2012-03-31 30
2011-12-31 28
2011-09-30 30
2011-06-30 29
2011-03-31 25
2010-12-31 23
2010-09-30 24
2010-06-30 24
2010-03-31 21
2009-12-31 21
2009-09-30 21
2009-06-30 20
2009-03-31 19
2008-12-31 19
2008-09-30 19
2008-06-30 19
2008-03-31 19
2007-12-31 18
2007-09-30 19
2007-06-30 19
2007-03-31 15
2006-12-31 13
2006-09-30 14
2006-06-30 13
2006-03-31 12
2005-12-31 8
2005-09-30 7
2005-06-30 7
2005-03-31 7
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.368B $0.156B
BioDelivery Sciences International is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology designed for a potentially broad base of pharmaceuticals, vaccines and over-the-counter drugs. In general, a drug delivery technology refers to any process, substance, or combination thereof, that delivers drugs into the body.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71